These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 19372929)

  • 1. HIV antiretroviral medications and hepatotoxicity.
    Cooper CL
    Curr Opin HIV AIDS; 2007 Nov; 2(6):466-73. PubMed ID: 19372929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatotoxicity and liver disease in the context of HIV therapy.
    Vogel M; Rockstroh JK
    Curr Opin HIV AIDS; 2007 Jul; 2(4):306-13. PubMed ID: 19372904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiretroviral therapy in coinfected patients: viral hepatitis and tuberculosis.
    Rockstroh JK; Hardy WD
    Curr Opin HIV AIDS; 2006 Sep; 1(5):442-8. PubMed ID: 19372845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis virus immune restoration disease of the liver.
    Crane M; Matthews G; Lewin SR
    Curr Opin HIV AIDS; 2008 Jul; 3(4):446-52. PubMed ID: 19373004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatotoxicity and antiretroviral therapy with protease inhibitors: A review.
    Bruno R; Sacchi P; Maiocchi L; Patruno S; Filice G
    Dig Liver Dis; 2006 Jun; 38(6):363-73. PubMed ID: 16631422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The VIRGO study: nevirapine, didanosine and stavudine combination therapy in antiretroviral-naive HIV-1-infected adults.
    Raffi F; Reliquet V; Ferré V; Arvieux C; Hascoet C; Bellein V; Besnier JM; Breux JP; Garré M; May T; Molina JM; Perré P; Raguin G; Rozenbaum W; Zucman D
    Antivir Ther; 2000 Dec; 5(4):267-72. PubMed ID: 11142621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Safety study of 52-week highly active antiretroviral therapy in 198 HIV/AIDS Chinese patients].
    Li WJ; Dai Y; Han Y; Qiu ZF; Xie J; Zuo LY; Li YL; Li TS
    Zhonghua Yi Xue Za Zhi; 2011 May; 91(19):1318-22. PubMed ID: 21756757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of antiretroviral therapy in the incidence of pancreatitis in HIV-positive individuals in the EuroSIDA study.
    Smith CJ; Olsen CH; Mocroft A; Viard JP; Staszewski S; Panos G; Staub T; Blaxhult A; Vetter N; Lundgren JD
    AIDS; 2008 Jan; 22(1):47-56. PubMed ID: 18090391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact and management of hepatitis B and hepatitis C virus co-infection in HIV patients.
    Kumar R; Singla V; Kacharya Sk
    Trop Gastroenterol; 2008; 29(3):136-47. PubMed ID: 19115605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management and therapy of chronic hepatitis C in HIV.
    Soriano V; Vispo E; Martin-Carbonero L; Labarga P; Garcia-Samaniego J; Barreiro P
    Curr Opin HIV AIDS; 2007 Nov; 2(6):482-8. PubMed ID: 19372931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Highly active antiretroviral therapy in HIV and hepatitis C coinfected individuals: friend or foe?
    Rockstroh J
    Curr Opin HIV AIDS; 2007 Nov; 2(6):449-53. PubMed ID: 19372926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors.
    Sulkowski MS
    Semin Liver Dis; 2003 May; 23(2):183-94. PubMed ID: 12800071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stavudine plus a non-thymidine nucleoside reverse transcriptase inhibitor as a backbone for highly active antiretroviral therapy.
    Clumeck N
    Antivir Ther; 1998; 3 Suppl 4():39-43. PubMed ID: 10723508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV and hepatitis C co-infection: the role of HAART in HIV/hepatitis C virus management.
    Jones M; Núñez M
    Curr Opin HIV AIDS; 2011 Nov; 6(6):546-52. PubMed ID: 22001896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stavudine plus didanosine and nevirapine in antiretroviral-naive HIV-infected adults: preliminary safety and efficacy results. VIRGO Study Team.
    Raffi F; Reliquet V; Francois C; Garre M; Hascoet C; Allavena C; Arvieux C; Breux JP; Perre P; Rozenbaum W; Auger S
    Antivir Ther; 1998; 3 Suppl 4():57-60. PubMed ID: 10723512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
    Molina JM; Chêuc G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM;
    Antivir Ther; 1999; 4 Suppl 3():71-4. PubMed ID: 16021874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse effects of antiretroviral therapy in HIV-1 infected children.
    Shah I
    J Trop Pediatr; 2006 Aug; 52(4):244-8. PubMed ID: 16126803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progression of liver fibrosis in patients coinfected with hepatitis C virus and human immunodeficiency virus undergoing antiretroviral therapy.
    Pineda JA; Macías J
    J Antimicrob Chemother; 2005 Apr; 55(4):417-9. PubMed ID: 15731202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of antiretroviral therapy on liver disease.
    Kovari H; Weber R
    Curr Opin HIV AIDS; 2011 Jul; 6(4):272-7. PubMed ID: 21508839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.